🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,589 results for “Pharma” Clear

  1. IMFINZI 50 mg/mL concentrate for solution for infusion., CARBOPLATIN , IMFINZI 50 mg/mL concentrate for solution for infusion., IMFINZI 50 mg/mL concentrate for solution for infusion., PEMETREXED , PACLITAXEL , IMFINZI 50 mg/mL concentrate for solution for infusion., IPH5201, CISPLATIN

    Lacuna Pharma Pty Ltd

    Non-Small Cell Lung Cancer II, III

    phase 2 small molecule active

    1 trial

  2. IMFINZI 50 mg/mL concentrate for solution for infusion., TREMELIMUMAB

    Pari Pharma GmbH

    Hepatocellular carcinoma

    phase 2 small molecule active

    1 trial

  3. IMX-110 combined with Tislelizumab

    Immix Biopharma

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  4. INC280

    Novartis Pharmaceuticals

    Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  5. INEBILIZUMAB

    Elan Pharma International

    Neuromyelitis optica spectrum disorder (NMOSD; also known as Devic's syndrome and previously known as neuromyelitis optica [NMO])

    phase 2 small molecule active

    1 trial

  6. INFLIXIMAB , TOCILIZUMAB , Cosentyx 300 mg solution for injection in pre-filled pen, ADALIMUMAB

    Pari Pharma GmbH

    TAkayasu ARteritiS

    phase 2 small molecule active

    1 trial

  7. INFLIXIMAB, RoActemra 20 mg/mL concentrate for solution for infusion

    Pari Pharma GmbH

    Takayasu arteritis

    phase 2 small molecule active

    1 trial

  8. INM-755 (cannabinol) cream

    InMed Pharmaceuticals

    Epidermolysis Bullosa Simplex

    phase 2 small molecule completed

    1 trial

  9. INO-3107

    INOVIO PHARMACEUTICALS, INC.

    Respiratory Papillomatosis

    phase 2 small molecule completed

    1 trial

  10. INO-3112

    INOVIO PHARMACEUTICALS, INC.

    Head and Neck Squamous Cell Cancer

    phase 2 mab completed

    1 trial

  11. INO-3112

    INOVIO PHARMACEUTICALS, INC.

    Cervical Cancer

    phase 2 mab completed

    1 trial

  12. INO-3112 vaccine

    INOVIO PHARMACEUTICALS, INC.

    Uterine Cervical Neoplasms

    phase 2 mab terminated

    1 trial

  13. INO-4700

    INOVIO PHARMACEUTICALS, INC.

    Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

    phase 2 small molecule completed

    1 trial

  14. INO-5401

    INOVIO PHARMACEUTICALS, INC.

    Glioblastoma

    phase 2 mab active

    1 trial

  15. INO-5401

    INOVIO PHARMACEUTICALS, INC.

    Urothelial Carcinoma

    phase 2 mab completed

    1 trial

  16. INTERFERON GAMMA , TOCILIZUMAB , DALTEPARIN , HEPARIN , BARICITINIB, FLUDROCORTISONE , HYDROCORTISONE, OCTAPLASLG, solution pour perfusion, BARICITINIB, ANAKINRA , FILGRASTIM

    Pari Pharma GmbH

    Sepsis

    phase 2 small molecule active

    1 trial

  17. INZ-701

    Lacuna Pharma Pty Ltd

    Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency and ATP-binding cassette sub-family C member 6 (ABCC6) Deficiency, Generalized Arterial Calcification of Infancy (GACI), Pseudoxanthoma elasticum (PXE)

    phase 2 small molecule active

    1 trial

  18. ION-682884

    IONIS PHARMACEUTICALS INC

    Healthy Volunteers

    phase 2 small molecule completed

    1 trial

  19. ION-827359

    IONIS PHARMACEUTICALS INC

    Chronic Bronchitis

    phase 2 small molecule terminated

    1 trial

  20. ION224

    IONIS PHARMACEUTICALS INC

    Steatohepatitis, Nonalcoholic

    phase 2 small molecule completed

    1 trial

  21. ION337

    IONIS PHARMACEUTICALS INC

    Dravet Syndrome

    phase 2 small molecule active

    1 trial

  22. ION373, Artificial Cerebrospinal Fluid (aCSF) for injection

    IONIS PHARMACEUTICALS INC

    Alexander Disease

    phase 2 small molecule active

    1 trial

  23. ION440

    IONIS PHARMACEUTICALS INC

    Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome

    phase 2 small molecule active

    1 trial

  24. ION440

    IONIS PHARMACEUTICALS INC

    Methyl CpG binding protein 2 (MECP2) Duplication Syndrome (MDS)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources